tiprankstipranks
Indaptus Therapeutics (INDP)
NASDAQ:INDP
US Market
Holding INDP?
Track your performance easily

Indaptus Therapeutics (INDP) Income Statement

478 Followers

Indaptus Therapeutics Income Statement

Last quarter (Q3 2024), Indaptus Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Indaptus Therapeutics's net income was $-3.07M. See Indaptus Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20
Total Revenue
----$ 0.00
Cost of Revenue
-----
Gross Profit
-----
Operating Expense
$ 7.49M$ 16.38M$ 14.91M$ 7.73M$ 3.60M
Operating Income
$ -15.37M$ -16.38M$ -14.91M$ -7.73M$ -3.60M
Net Non Operating Interest Income Expense
--$ -588.11K$ 17.72K$ 15.11K
Other Income Expense
$ 1.43M$ 955.00K$ 588.11K--
Pretax Income
$ -7.01M$ -15.42M$ -14.32M$ -7.71M$ -3.58M
Tax Provision
$ 13.92K$ 13.92K$ -8.80K$ -44.33K-
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ -14.89M$ -15.42M$ -14.32M$ -7.71M$ -3.58M
Basic EPS
$ -1.70$ -1.83$ -1.73-$ -0.66
Diluted EPS
$ -1.70$ -1.83$ -1.73$ -1.89$ -0.66
Basic Average Shares
$ 34.90M$ 8.40M$ 8.26M$ 4.09M$ 5.41M
Diluted Average Shares
$ 34.90M$ 8.40M$ 8.26M$ 4.09M$ 5.41M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 7.49M$ 16.38M$ 14.91M$ 7.73M$ 3.60M
Net Income From Continuing And Discontinued Operation
$ -14.89M$ -15.42M$ -14.32M$ -7.71M$ -3.58M
Normalized Income
$ -6.14M$ -12.18M--$ -3.58M
Interest Expense
-----
EBIT
$ -7.18M$ -16.38M$ -14.91M$ -7.71M$ -3.60M
EBITDA
$ -7.18M$ -16.38M$ -14.91M$ -7.71M$ -3.60M
Currency in USD

Indaptus Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis